

## NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE


# **Single Technology Appraisal**

# Larotrectinib for treating NTRK fusion-positive advanced solid tumours (Managed access review of TA630) [ID6292]


## **Final Stakeholder List**

Consultees	Commentators (no right to submit or appeal)
<ul><li>Company</li><li>Bayer (larotrectinib)</li></ul>	<ul><li>General</li><li>All Wales Therapeutics and Toxicology</li></ul>
Dayer (larotreetimb)	Centre Centre
Patient/carer groups	Allied Health Professionals Federation
Action Kidney Cancer     Anthony Dilabor Rone Cancer Trust	Board of Community Health Councils in  Walsa
<ul><li>Anthony Pilcher Bone Cancer Trust</li><li>Asthma + Lung Foundation</li></ul>	Wales  ● British National Formulary
Black Health Agency for Equality	Care Quality Commission
Bob Champion Cancer Trust	Department of Health - Northern Ireland
Bowel Cancer UK	Healthcare Improvement Scotland
Breast Cancer Now	Medicines and Healthcare products
Breast Cancer UK	Regulatory Agency
British Skin Foundation	National Association of Primary Care
Butterfly Thyroid Cancer Trust	National Pharmacy Association
• Cancer 52	NHS Confederation     NHS Walsa Isint Commissioning
Cancer Black Care     Cancer Lawrence Trust	<ul> <li>NHS Wales Joint Commissioning Committee</li> </ul>
<ul><li>Cancer Laryngectomee Trust</li><li>Changing Faces</li></ul>	Scottish Medicines Consortium
Childhood Cancer Parents Alliance	Welsh Government
Children's Cancer and Leukaemia	
Group	Possible comparator companies
Children with Cancer	• None
Genetic Alliance UK	
Get-A-Head	Relevant research groups
GIST Cancer UK	Against Breast Cancer     Bana Cancer Basacrah Trust
Helen Rollason Cancer Charity	<ul><li>Bone Cancer Research Trust</li><li>Bone Research Society</li></ul>
Independent Cancer Patients Voice      Idea and Canada All	Breast Cancer Hope
Kidney Care UK     Kidney Care UK	Breast Cancer Research Trust
<ul><li>Kidney Care UK</li><li>Kidney Research UK</li></ul>	Cochrane Breast Cancer Group
Let's Face It	Cochrane Childhood Cancer Group
Macmillan Cancer Support	Cochrane Lung Cancer Group
Maggie's Centres	Cochrane Prostatic Diseases Urologic
Marie Curie	Cancers Group
Mouth Cancer Foundation	Cochrane Skin Group     Conomics England
	Genomics England

Final stakeholder list for the evaluation of larotrectinib for treating NTRK fusion-positive advanced solid tumours (MA review of TA630) [ID6292]



#### Consultees Commentators (no right to submit or appeal) National Association of Institute of Cancer Research Laryngectomee Clubs Melanoma Fund National Kidney Federation MRC Clinical Trials Unit **NTRKers** National Institute for Health Research Orchid – Fighting Male Cancer **Oracle Cancer Trust OUTpatients** Pro Cancer Research Fund Prostate Cancer UK **Prostate Cancer Research Centre** Roy Castle Lung Cancer Foundation Research Institute for the Care of Older Sarcoma UK People Skin Cancer Research Fund Solving Kid's Cancer South Asian Health Foundation Skin Treatment & Research Trust Specialised Healthcare Alliance Associated Public Health groups Swallows Head and Neck Cancer **Public Health Wales** Support Group Teenage Cancer Trust UK Health Security Agency **Tenovus Cancer Care** The Royal Marsden Cancer Charity Together for Short Lives **UK Lung Cancer Coalition** Women's Health Concern Young Lives vs Cancer Professional groups Association of Anaesthetists Association of Cancer Physicians Association of Respiratory Nurse **Specialists** Association of Surgeons of Great Britain and Ireland **British Association of Dermatologists** British Association of Endocrine and **Thyroid Surgeons British Association of Surgical** Oncology British Association of Urological Surgeons **British Dermatological Nursing Group British Geriatrics Society** British Institute of Radiology **British Oncology Pharmacy** Association **British Orthopaedic Association** British Orthopaedic Oncology Society British Psychosocial Oncology Society




Consultees	Commentators (no right to submit or appeal)
<ul> <li>British Sarcoma Group</li> <li>British Society for Dermatological Surgery</li> <li>British Society of Skeletal Radiologists</li> <li>British Society of Urogenital Radiology</li> <li>British Thoracic Oncology Group</li> <li>British Thoracic Society</li> <li>British Thyroid Association</li> <li>British Uro-oncology Group</li> <li>Cancer Research UK</li> <li>CCLG: The Children &amp; Young People's Cancer Association</li> <li>Lung Cancer Nursing UK</li> <li>Melanoma Focus</li> <li>Pelican Cancer Foundation</li> <li>Primary Care Dermatology Society</li> <li>Royal College of Anaesthetists</li> <li>Royal College of General Practitioners</li> <li>Royal College of Paediatricians and Child Health</li> <li>Royal College of Pathologists</li> <li>Royal College of Physicians</li> <li>Royal College of Radiologists</li> <li>Royal College of Surgeons</li> <li>Royal College of Surgeons</li> <li>Royal Pharmaceutical Society</li> <li>Royal Society of Medicine</li> <li>Society and College of Radiographers</li> <li>UK Clinical Pharmacy Association</li> <li>UK Kidney Association</li> <li>UK Oncology Nursing Society</li> <li>UK Renal Pharmacy Group</li> </ul>	
<ul><li>Others</li><li>Department of Health and Social Care</li><li>NHS England</li></ul>	

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.

# **Definitions:**

Final stakeholder list for the evaluation of larotrectinib for treating NTRK fusion-positive advanced solid tumours (MA review of TA630) [ID6292]



Consultee or commentator stakeholders are provisional until a signed Confidentiality Agreement & Undertaking form is submitted to NICE at the evaluation stage. Participating stakeholders will be listed on the project information page for the evaluation.

#### Consultees

Organisations that accept an invitation to participate in the evaluation; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts and has the right to appeal against the Final Draft Guidance (FDG).

All non-company consultees are invited to submit a statement relevant to the group they are representing, respond to consultations, nominate clinical or patient experts and have the right to appeal against the Final Draft Guidance (FDG).

#### Commentators

Organisations that engage in the evaluation process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FDG for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC]); other groups (for example, the NHS Confederation and the British National Formulary).

All non-company commentators are invited to nominate clinical or patient experts.